- Home
- CHRS vs FENC Comparison
CHRS vs FENC Comparison
Compare CHRS & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- FENC
- Stock Information
- Founded
- CHRS 2010
- FENC 1996
- Country
- CHRS United States
- FENC United States
- Employees
- CHRS N/A
- FENC N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- FENC Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CHRS Health Care
- FENC Health Care
- Exchange
- CHRS Nasdaq
- FENC Nasdaq
- Market Cap
- CHRS 84.2M
- FENC 222.9M
- IPO Year
- CHRS 2014
- FENC 2001
- Fundamental
- Price
- CHRS $0.82
- FENC $8.40
- Analyst Decision
- CHRS Buy
- FENC Strong Buy
- Analyst Count
- CHRS 3
- FENC 2
- Target Price
- CHRS $4.68
- FENC $13.00
- AVG Volume (30 Days)
- CHRS 1.3M
- FENC 80.0K
- Earning Date
- CHRS 08-07-2025
- FENC 08-12-2025
- Dividend Yield
- CHRS N/A
- FENC N/A
- EPS Growth
- CHRS N/A
- FENC N/A
- EPS
- CHRS N/A
- FENC N/A
- Revenue
- CHRS $272,251,000.00
- FENC $30,912,000.00
- Revenue This Year
- CHRS N/A
- FENC $0.85
- Revenue Next Year
- CHRS $106.56
- FENC $55.16
- P/E Ratio
- CHRS $1.87
- FENC N/A
- Revenue Growth
- CHRS 19.87
- FENC N/A
- 52 Week Low
- CHRS $0.66
- FENC $3.96
- 52 Week High
- CHRS $2.43
- FENC $8.88
- Technical
- Relative Strength Index (RSI)
- CHRS 53.13
- FENC 63.33
- Support Level
- CHRS $0.72
- FENC $7.94
- Resistance Level
- CHRS $0.77
- FENC $8.51
- Average True Range (ATR)
- CHRS 0.04
- FENC 0.41
- MACD
- CHRS 0.01
- FENC -0.01
- Stochastic Oscillator
- CHRS 91.62
- FENC 89.80
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.